Mechanism of erythropoietin-induced hypertension

Chronic administration of erythropoietin (EPO) is associated with an increase in arterial blood pressure in patients and animals with chronic renal failure (CRF). Several mechanisms have been considered in the pathogenesis of EPO-induced hypertension. These include the possible role of the rise of h...

Full description

Saved in:
Bibliographic Details
Published inAmerican journal of kidney diseases Vol. 33; no. 5; p. 821
Main Author Vaziri, N D
Format Journal Article
LanguageEnglish
Published United States 01.05.1999
Subjects
Anemia - complications
Anemia - drug therapy
Animals
Catecholamines - blood
Endothelins - blood
Erythrocyte Volume
Erythropoietin - adverse effects
Erythropoietin - pharmacology
Erythropoietin - therapeutic use
Hematocrit
Humans
Hypertension - blood
Hypertension - chemically induced
Hypertension - etiology
Kidney Failure, Chronic - complications
Renin-Angiotensin System - physiology
Time Factors
Vasoconstrictor Agents - adverse effects
Vasoconstrictor Agents - therapeutic use
Online AccessGet more information

Cover

More Information
Summary:Chronic administration of erythropoietin (EPO) is associated with an increase in arterial blood pressure in patients and animals with chronic renal failure (CRF). Several mechanisms have been considered in the pathogenesis of EPO-induced hypertension. These include the possible role of the rise of hematocrit and erythrocyte mass, changes in production or sensitivity to endogenous vasopressors, alterations in vascular smooth-muscle ionic milieu, dysregulation of production or responsiveness to endogenous vasodilatory factors, a direct vasopressor action of EPO, and finally arterial remodeling through stimulation of vascular cell growth.
ISSN:1523-6838
DOI:10.1016/s0272-6386(99)70413-0